Drug profile · INN
lacosamide
LACOMED
lacosamide (LACOMED) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lacosamide
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
lacosamide (LACOMED) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lacosamide?
lacosamide (LACOMED) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lacosamide?
LACOMED is a marketed brand name for lacosamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lacosamide?
lacosamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.